Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03557203` - Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis
Completed	`NCT03379311` - A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis	Phase 1
Recruiting	`NCT04973384` - Ocular Comorbidity in Atopic Dermatitis
Completed	`NCT00987467` - Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis	N/A

See also

Status

Clinical Trial

Phase

Recruiting

NCT03557203 - Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis

Completed

NCT03379311 - A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

Phase 1

Recruiting

NCT04973384 - Ocular Comorbidity in Atopic Dermatitis

Completed

NCT00987467 - Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04296864
Study type	Interventional
Source	Andover Eye Associates
Contact	Kara Quealy
Phone	978-332-9417
Email	kquealy@andovereye.org
Status	Recruiting
Phase	Phase 2
Start date	February 10, 2020
Completion date	January 2025

Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms